Try Ask OE! Our NEW Advanced AI Enabled Search
Dive into the Largest Database of
Musculoskeletal Evidence
ACE Reports.
Arthroplasty
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial
Jama. 2020 ;():. 10.1001/jama.2019.20687
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial
This report has been verified by one or more authors of the original publication.
Jama. 2020 ;():. 10.1001/jama.2019.20687
Arthroplasty
Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3)
Thromb Haemost. 2014 Jan 29;111(2):213-25. doi: 10.1160/TH13-04-0296.
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3)
This report has been verified by one or more authors of the original publication.
Thromb Haemost. 2014 Jan 29;111(2):213-25. doi: 10.1160/TH13-04-0296.
General Orthopaedics
Extended Venous Thromboembolism (VTE) Prophylaxis after Hip Fracture Surgery with the Ultra-Low-Molecular-Weight Heparin(ULMWH) Semuloparin
Extended Venous Thromboembolism (VTE) Prophylaxis after Hip Fracture Surgery with the Ultra-Low-Molecular-Weight Heparin(ULMWH) Semuloparin
General Orthopaedics
Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study
Bone Joint J. 2013 Apr 1;95-B(4):459-66. doi: 10.1302/0301-620X.95B4.30730
Includes Author Interview
Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study
This report has been verified by one or more authors of the original publication.
Bone Joint J. 2013 Apr 1;95-B(4):459-66. doi: 10.1302/0301-620X.95B4.30730
Arthroplasty
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial
Lancet. 2009 May 16;373(9676):1673-80. Epub 2009 May 4
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial
This report has been verified by one or more authors of the original publication.
Lancet. 2009 May 16;373(9676):1673-80. Epub 2009 May 4
Arthroplasty
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial
Lancet. 2010 Mar 6;375(9717):807-15.
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial
Lancet. 2010 Mar 6;375(9717):807-15.